WHWen-Feng Hsu

Wen-Feng Hsu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Wen-Feng Hsu has a total of 104 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Impact of Baseline Synchronous Adenoma Burden on the Risk of Metachronous Advanced Neoplasia

    by Wei-Yuan Chang, Li-Chun Chang, Chu-Kuang Chou, Cheng-Hao Tseng, Chi-Yang Chang, Chi-Yi Chen, Wen-Feng Hsu, Yen-Nien Chen, Chieh-Chang Chen, Chia-Hung Tu, et al.

    INTRODUCTION: and study aim: Individuals classified as high-risk at initial colonoscopy face an elevated risk of metachronous advanced colorectal neoplasms (meta-ACRN), but risk heterogeneity within this group remains unclear. We aimed to stratify meta-ACRN risk among high-risk individuals based on their synchronous neoplastic burden. METHODS: This prospective cohort study used data from a Taiwanese multicenter trial (NCT03373136). We included participants with conventional high-risk findings (3–10 low-risk adenomas [LRAs] or any high-risk adenoma [HRA]). The primary outcome was meta-ACRN incidence. Adjusted incidence rate ratios (aIRRs) were calculated using multivariable Poisson regression, stratifying patients by baseline synchronous burden, with the 3–4 LRAs group as reference. RESULTS: Among 730 participants undergoing surveillance (mean follow-up 2.4 years), 81 (11.1%) developed meta-ACRN. A single HRA did not significantly increase meta-ACRN risk compared with 3–4 LRAs (aIRR 2.02; 95% confidence interval (CI) 0.83–4.90). However, risk escalated significantly when the index HRA was accompanied by synchronous LRA(s) (aIRR 2.56; 95% CI 1.24–5.39) or synchronous HRA(s) (aIRR 3.93; 95% CI 1.77–8.73) ( P for trend = 0.001). Furthermore, applying a more severe modified advanced adenoma criteria, an identical dose-response pattern emerged, culminating in a >5-fold increased risk of severe metachronous outcomes (aIRR 5.23; 95% CI 1.50–18.22) when accompanied by synchronous HRA(s). DISCUSSION: Meta-ACRN risk within the conventional high-risk population is highly heterogeneous and driven primarily by baseline synchronous neoplastic burden. Surveillance intervals should be personalized, reserving shorter intervals for patients with advanced lesions accompanied by synchronous adenomas.

  • Population Colorectal Cancer Screening in Asia: Insights From Established Programs

    by Wen‐Feng Hsu, Masau Sekiguchi, Jeongkuk Seo, Hyun‐Soo Kim, Takahisa Matsuda, Han‐Mo Chiu

    Background and Aims: Colorectal cancer (CRC) is a major public health challenge, with Asia now the global epicenter. In response, population‐based screening has become a cornerstone of CRC control in the region. This review provides a comprehensive analysis of the established national screening programs in Japan, South Korea, and Taiwan, comparing strategies, effectiveness, and quality assurance (QA) frameworks to identify key challenges and future directions. Methods: We analyzed program governance, screening strategies, effectiveness data, QA frameworks, and cost‐effectiveness, as well as emerging policies addressing issues such as young‐onset CRC. Results: The population‐based screening programs in all three countries primarily utilize the fecal immunochemical test (FIT) and have demonstrably reduced CRC mortality. While FIT remains the backbone of these programs, colonoscopy is being increasingly explored as a potential primary strategy in select contexts, but its capacity and manpower remain a concern for its use in population screening. QA is central to maintaining effectiveness. Cost‐effectiveness analyses generally support both FIT‐based and colonoscopy‐based approaches, with risk‐adapted strategies appearing to be the most efficient. Recent evidence highlights the importance of earlier initiation of screening in Asia, reflecting the rising incidence of young‐onset CRC. Conclusion: Population‐based FIT‐based screening is a highly effective public health strategy in East Asia. The future of CRC screening is a personalized paradigm, adapting policies such as lowering the screening age based on regional evidence and implementing risk stratification to build upon current successes and further mitigate the region's disease burden.


  • Open Access

    Cold Snare Polypectomy and Cold Endoscopic Mucosal Resection Versus Hot Endoscopic Mucosal Resection for Intermediate‐Size Sessile Serrated Lesions: A Randomized Controlled Trial

    by Li‐Chun Chang, Andrew Y. Wang, Cheng‐Hao Tseng, Yen‐Nien Chen, Chia‐Hung Tu, Wen‐Feng Hsu, Ming‐Shiang Wu, Han‐Mo Chiu, Taiwan Cold Snare (Tacos) Working Group

    Background: The current guidelines recommend cold snare polypectomy (CSP) for removing intermediate‐size sessile serrated lesions (SSLs) measuring 10–20 mm. However, these supporting data come from single‐arm or retrospective studies, underscoring the need for randomized controlled trials to confirm its efficacy. This study aimed to compare the efficacy of CSP and cold endoscopic mucosal resection (EMR) with that of hot EMR in achieving complete histological resection of intermediate‐size SSLs. Methods: This was a multicenter, randomized, non‐inferiority trial. A total of 113 patients with 159 intermediate‐size SSLs were randomized into three groups: CSP, cold EMR, and hot EMR. The primary outcome was the complete histological resection, defined as tumor‐free horizontal and vertical margins, regardless of whether resection was en bloc or piecemeal. Secondary outcomes included en bloc resection rate, polypectomy time, and procedural complications. Results: The complete histological resection rates were 90.6% for CSP, 88.5% for cold EMR, and 87.0% for hot EMR, demonstrating the non‐inferiority of CSP and cold EMR compared to hot EMR. CSP had a shallower vertical resection depth, which was improved by submucosal injection. CSP also had shorter polypectomy and total procedure times. The En bloc resection rates were 69.8% for CSP, 78.9% for cold EMR, and 88.9% for hot EMR. Although the en bloc resection rate was lower with CSP compared with hot EMR, it improved with submucosal injection. Discussion: CSP and cold EMR are effective alternatives to hot EMR for removing intermediate‐size SSLs, providing strong support for their recommendations in guidelines. Further research is warranted to evaluate the long‐term residual rate.


  • Open Access

    Bleeding Risk of Cold Versus Hot Snare Polypectomy for Pedunculated Colorectal Polyps Measuring 10 mm or Less: Subgroup Analysis of a Large Randomized Controlled Trial

    by Cheng-Hao Tseng, Li-Chun Chang, Jia-Ling Wu, Chi-Yang Chang, Chi-Yi Chen, Peng-Jen Chen, Chia-Tung Shun, Wen-Feng Hsu, Yen-Nien Chen, Chieh-Chang Chen, et al.

    INTRODUCTION: Concerns regarding bleeding remain in cold snare polypectomy (CSP) for small pedunculated (0-Ip) polyps. The aim of this study was to compare the risk of CSP and hot snare polypectomy (HSP) for such lesions. METHODS: Data on 0-Ip colorectal polyps ≤10 mm were extracted from a large, pragmatic, randomized trial. Immediate postpolypectomy bleeding (IPPB), defined as the perioperative use of a clip for bleeding, was evaluated through polyp-level analysis. Delayed postpolypectomy bleeding (DPPB), defined as bleeding occurring within 2 weeks postoperatively, was assessed at the patient-level among patients whose polyps were all ≤10 mm, including at least one 0-Ip polyp. RESULTS: A total of 647 0-Ip polyps (CSP: 306; HSP: 341) were included for IPPB analysis and 386 patients (CSP: 192; HSP: 194) for DPPB analysis. CSP was associated with a higher incidence of IPPB (10.8% vs 3.2%, P < 0.001) but no adverse clinical events. The procedure time of all polypectomies was shorter for CSP than for HSP (123.0 ± 117.8 vs 166.0 ± 237.7 seconds, P = 0.003), while the procedure time of polypectomies with IPPB were similar (249.8 ± 140.2 vs 227.4 ± 125.9 seconds, P = 0.64). DPPB was observed in 3 patients (1.5%) in the HSP group, including one patient (0.5%) with severe bleeding, but not in the CSP group. DISCUSSION: Despite CSP being associated with more IPPB events, it could be timely treated without adverse outcomes. Notably, no delayed bleeding occurred in the CSP group. Our findings support the use of CSP for 0-Ip polyps ≤ 10 mm.


  • Sa1169 IMPLEMENTATION OF THE NOVEL AI-BASED CECAL RECOGNITION SYSTEM IMPROVED THE ADENOMA DETECTION RATE IN SCREENING COLONOSCOPY

    by Wen-Feng Hsu, Li-Chun Chang, Wei-Yuan Chang, Hsuan-Ho Lin, Chen Ya Kuo, Ming-Shiang Wu, Han-Mo Chiu

  • Open Access

    Double‐contrast barium enema is no longer justified as a backup examination for colonoscopy in the population screening program: Population study in an organized fecal immunochemical test‐based screening program

    by Wen‐Feng Hsu, Chiu‐Wen Su, Chen‐Yang Hsu, Amy Ming‐Fang Yen, Sam Li‐Sheng Chen, Sherry Yueh‐Hsia Chiu, Yi‐Chia Lee, Tsui‐Hsia Hsu, Li‐Ju Lin, Shu‐Li Chia, et al.

    Background and Aim: Currently, some countries still acknowledge double‐contrast barium enema (DCBE) as a backup confirmatory examination when colonoscopy is not feasible or incomplete in colorectal cancer (CRC) screening programs. This study aims to compare the performance of colonoscopy and DCBE in terms of the risk of incident CRC after negative results in the fecal immunochemical test (FIT)‐based Taiwan Colorectal Cancer Screening Program.Methods: Subjects who had positive FITs and received confirmatory exams, either colonoscopy or DCBE, without the findings of neoplastic lesions from 2004 to 2013 in the screening program comprised the study cohort. Both the colonoscopy and DCBE subcohorts were followed until the end of 2018 and linked to the Taiwan Cancer Registry to identify incident CRC cases. Multivariate analysis was conducted to compare the risk of incident CRC in both subcohorts after controlling for potential confounders.Results: A total of 102 761 colonoscopies and 5885 DCBEs were performed after positive FITs without neoplastic findings during the study period. By the end of 2018, 2113 CRCs (2.7 per 1000 person‐years) and 368 CRCs (7.6 per 1000 person‐years) occurred in the colonoscopy and DCBE subcohorts, respectively. After adjusting for major confounders, DCBE had a significantly higher risk of incident CRC than colonoscopy, with an adjusted HR of 2.81 (95% CI = 2.51–3.14).Conclusions: In the FIT screening program, using DCBE as a backup examination was associated with a nearly threefold risk of incident CRC compared with colonoscopy, demonstrating that it is no longer justified as a backup examination for incomplete colonoscopy.


  • Top Cited Papers

    Cold Versus Hot Snare Polypectomy for Small Colorectal Polyps

    by Li-Chun Chang, Chi-Yang Chang, Chi-Yi Chen, Cheng-Hao Tseng, Peng-Jen Chen, Chia-Tung Shun, Wen-Feng Hsu, Yen-Nien Chen, Chieh-Chang Chen, Tien-Yu Huang, et al.

    Although cold snare polypectomy (CSP) is considered effective in reducing delayed postpolypectomy bleeding risk, direct evidence supporting its safety in the general population remains lacking. To clarify whether CSP would reduce delayed bleeding risk after polypectomy compared with hot snare polypectomy (HSP) in the general population. Multicenter randomized controlled study. (ClinicalTrials.gov: NCT03373136). 6 sites in Taiwan, July 2018 through July 2020. Participants aged 40 years or older with polyps of 4 to 10 mm. CSP or HSP to remove polyps of 4 to 10 mm. The primary outcome was the delayed bleeding rate within 14 days after polypectomy. Severe bleeding was defined as a decrease in hemoglobin concentration of 20 g/L or more, requiring transfusion or hemostasis. Secondary outcomes included mean polypectomy time, successful tissue retrieval, en bloc resection, complete histologic resection, and emergency service visits. A total of 4270 participants were randomly assigned (2137 to CSP and 2133 to HSP). Eight patients (0.4%) in the CSP group and 31 (1.5%) in the HSP group had delayed bleeding (risk difference, -1.1% [95% CI, -1.7% to -0.5%]). Severe delayed bleeding was also lower in the CSP group (1 [0.05%] vs. 8 [0.4%] events; risk difference, -0.3% [CI, -0.6% to -0.05%]). Mean polypectomy time (119.0 vs. 162.9 seconds; difference in mean, -44.0 seconds [CI, -53.1 to -34.9 seconds]) was shorter in the CSP group, although successful tissue retrieval, en bloc resection, and complete histologic resection did not differ. The CSP group had fewer emergency service visits than the HSP group (4 [0.2%] vs. 13 [0.6%] visits; risk difference, -0.4% [CI, -0.8% to -0.04%]). An open-label, single-blind trial. Compared with HSP, CSP for small colorectal polyps significantly reduces the risk for delayed postpolypectomy bleeding, including severe events. Boston Scientific Corporation.


  • Open Access

    Impact of COVID‐19 pandemic on fecal immunochemical test screening uptake and compliance to diagnostic colonoscopy

    by Shao‐Yi Cheng, Chu‐Fen Chen, Hsien‐Chin He, Li‐Chun Chang, Wen‐Feng Hsu, Ming‐Shiang Wu, Han‐Mo Chiu

    Background and Aim: During this COVID‐19 pandemic, Taiwan is one of the few countries where fecal immunochemical test and endoscopic activity for colorectal cancer screening keeps ongoing. We aimed to investigate how screening uptake and colonoscopy rate were affected in one of the biggest screening hubs in Northern Taiwan.Methods: We conducted a prospective observational study tracing and analyzing the screening uptake and the trend of compliance to diagnostic colonoscopy in fecal immunochemical test‐positive subjects in the National Taiwan University Hospital screening hub since the outbreak of COVID‐19 and compared it with that of the corresponding periods in the past 3 years. Cancellation and rescheduling rates of colonoscopy and related reasons were also explored.Results: Screening uptake during December 2019 to April 2020 was 88.8%, which was significantly lower than that in the corresponding period of the past 3 years (91.2–92.7%, P for trend < 0.0001). Colonoscopy rate in this period was 66.1%, which was also significantly lower than that in the past 3 years (70.2–77.5%, P for trend = 0.017). Rescheduling or cancellation rate was up to 10.9%, which was significantly higher than that in the past 3 years (P for trend = 0.023), and half of them was due to the fear of being infected.Conclusion: Fecal immunochemical test screening was significantly affected by COVID‐19 pandemic. In order to resume the practice in COVID‐19 era, screening organizers should consider various approaches to secure timely diagnosis of colorectal cancer.


  • Higher risk of advanced histology in adenoma less than 10 mm in fecal immunochemical test screening: Implication for management

    by Wen‐Feng Hsu, Shao‐Yi Cheng, Chia‐Tung Shun, Li‐Chun Chang, Chia‐Hung Tu, Hsiu‐Po Wang, Ming‐Shiang Wu, Han‐Mo Chiu

    Background and Aim: Whether diminutive or small adenomas detected by fecal immunochemical tests (FITs) are associated with a higher risk of advanced histology remains unknown. We investigated the prevalence of advanced histology in diminutive and small adenomas detected by FIT and compared with that detected by colonoscopy screening.Methods: We prospectively compared 1860 FIT‐positive patients (FIT‐positive cohort) and 6691 average‐risk patients (screening colonoscopy cohort). Both groups underwent colonoscopies and were shown to have neoplastic lesions. The prevalence of advanced histology was determined, as was the associations with size and FIT positivity.Results: We analyzed 3920 neoplastic lesions from the FIT‐positive cohort and 9789 neoplastic lesions from the screening colonoscopy cohort. Eighty (4.3%) diminutive lesions in FIT‐positive cohort had advanced histology but without any invasive cancer. Twenty‐one patients in the FIT‐positive cohort and 49 in the screening colonoscopy cohort with diminutive adenomas displayed advanced histology (3.5% vs 1.2%; adjusted odds ratio [aOR] = 2.99, 95% confidence interval [CI]: 1.77–5.06). Sixteen patients in the FIT‐positive cohort (2.7%) with diminutive adenomas might have changed the surveillance interval if a resect‐and‐discard strategy was applied, with a higher likelihood compared with the screening colonoscopy cohort (aOR = 2.76, 95% CI: 1.53–4.99).Conclusions: Fecal immunochemical test screening detected more diminutive and small adenomas with advanced histology compared with colonoscopy screening. Its impact on current management of diminutive polyp is limited.